INTRODUCTION
Assisted reproduction techniques (ART) represent an alternative mode of treatment in patients with polycystic ovarian syndrome (PCOS) and longstanding infertility resistant to other in vivo treatment modalities. In vitro fertilization (IVF) can also be applied to PCOS patients due to the coexistence of another infertility factor (1) . Moreover, application of IVF provides the opportunity to assess the fertilizing potential of the gametes (1) , bypassing factors such as lack of follicle rupture, oocyte entrapment within ruptured follicles, mechanical difficulties of the fimbria to reach all surfaces of the enlarged ovary, and abnormalities of sperm or embryo transport which can be implicated in the in vivo fertilizing process (2) .
Raised tonic levels of luteinizing hormone (LH) are one of the main endocrinological disturbances in PCOS patients. This inappropriate secretion of LH seems to affect both fertility and pregnancy outcomes of PCOS women attempting either natural conception or conception after medical ovulation induction (1, 3) .
In PCOS patients stimulated for IVF, increased LH levels seem to have an adverse effect on follicle and oocyte development, thus impairing the ovar-
The opinions presented in this column are those of its authors and do not necessarily reflect those of the journal and its editors, publisher, and advertisers. Jan response to stimulation and the ART results (1, 3, 4) . Qn the other hand, the use of gonadotropinreleasing hormone analogues (GnRH-a) in the long desensitization protocol suppresses endogenous LH production and prevents premature LH surges, exerting a beneficial effect on ART results (1, (4) (5) (6) .
FOLLICLE AND OOCYTE DEVELOPMENT
A multifollicular response is commonly observed in patients with PCOS stimulated for various ART (1) . However, the numbers of follicles developed and oocytes retrieved were found to be inversely related to the baseline LH: follicle stimulating hormone (FSH) ratio in women stimulated with human menopausal gonadotropin (HMG) only for IVF (4) , supporting the adverse effect of LH on follicular and oocyte development. The addition of GnRH-a in the long desensitization protocol seems to reverse the deleterious effect of high follicular tonic LH levels on follicle and oocyte development since the number of follicles and oocytes remains relatively constant irrespective of the basal LH:FSH ratio (4). Moreover, suppression of the pituitaryovarian axis with GnRH-a appears to improve follicular synchrony in PCOS women stimulated for IVF (7) . An increase in the number of ova after GnRHa treatment was also observed (8, 9) , especially in hyperandrogenic patients, supporting the deleterious action of LH on follicular and oocyte development. The observation that no difference in oocyte number exists in women stimulated with FSH/HMG versus GnRH-a plus FSH/HMG (10) is probably due to the use of FSH in addition to HMG which may partly counteract the adverse effects of LH in those patients stimulated without GnRH-a and further supports the negative impact of unbalanced LH on follicles and oocytes.
These findings probably reflect the intrafollicular endocrinological disturbances described in PCOS. The increased production of androgens associated with the high LH concentrations, coupled with their inefficient aromatization to estrogens related to the relatively low FSH levels in PCOS patients, results in a local androgen excess and estrogen deficit within the ovary (4, 7) . This would constitute a very potent atrogenic environment for the follicle, leading to the cessation of follicular growth. The atrogenic effect of LH through excessive androgen production is also supported by the finding that the LH:FSH ratio in PCOS patients was positively correlated with androstenedione (11) . On the other hand, treatment with GnRH-a suppresses LH secretion, preventing follicle exposure to high endogenous gonadotropins, thus leading to a selfcontrolled mechanism in follicular growth and selection without inducing generalized follicular atresia (12) .
OOCYTE QUALITY
PCOS patients.stimulated for IVF were found.to have a higher percentage of immature oocytes compared with normoovulatory women (13) . Increased follicular-phase LH concentrations seem to influence the quality of the oocytes obtained. An inverse correlation between the LH:FSH ratio and mature oocytes in PCOS patients stimulated for IVF with HMG, or with GnRH-a plus HMG, was reported (4). Moreover, a reliable marker of oocyte quality is their fertilization rate, and several investigators (3, 14, 15) have reported that increased LH levels significantly reduced the fertilization and cleavage rates. The administration of GnRH-a seems to have a beneficial effect on oocyte quality by reversing, at least partly, the adverse effect of raised serum LH levels in PCOS patients (4) . The beneficial effect of GnRH-a was also confirmed by Turhan et al. (7) , who observed an increased number of mature oocytes in PCQS women stimulated with GnRHa/HMG for IVF, compared with those stimulated without GnRH-a, as well as by Homburg eta/. (5), who also reported higher fertilization rates in this group of PCOS women.
Thus, it seems that high LH concentrations may interfere with oocyte maturity either directly through an influence on the oocyte maturation inhibitor (3) or indirectly through androgens (3, 16) . The augmented androgen production by LH (11, 16) may either lead to follicular atresia, thus decreasing the number of eggs obtained, or adversely affect oocyte quality (3, 4, 16) . The use of GnRH-a appears to correct partly the influence of LH on oocyte quality. This partial effect is probably due to the incomplete suppression of bioactive LH (17) .
PREGNANCY OUTCOME
Pregnancy rates in patients with PCOS undergoing IVF are similar to those in normoovulatory women. Thus, it seems that despite the aforementioned poorer quality of retrieved oocytes and lower fertilization and cleavage rates, if two or three healthy embryos are obtained, their replacement in utero gives equal chances of implantation and pregnancy (1, 18) . However, once a pregnancy is established, high miscarriage rates represent a common and frustrating complication in these women. This seems also to be related to the inappropriately raised serum LH concentrations. Homburg et al. (19) found an association between follicular-phase serum LH levels and miscarriages in women who underwent ovulation induction. This was further confirmed by Hamilton-Fairley et aL (20) , in PCOS patients treated with a low-dose gonadotropin regime.
The use of GnRH-a followed by gonadotropin stimulation either for ovulation induction or for IVF is thought to reduce the incidence of early abortions. Only 9% of women with recurrent spontaneous abortions after clomiphene citrate (CC) treatment had a repeat spontaneous miscarriage when they were treated with buserelin acetate plus FSH, compared to 48% of women treated with CC alone (21). Moreover, treatment of anovulatory PCOS women with GnRH-a/HMG reduced the miscarriage rate and improved the live birth rate compared to treatment with gonadotropins alone (5). However, GnRH-a does not disrupt the association between raised LH concentrations and early abortions. Our group (4) showed that PCOS patients who miscarried after GnRH-a/HMG stimulation for IVF had significantly higher LH:FSH ratios than those who had a live birth. The use of GnRH-a does not appear to prevent this complication entirely either because of the incomplete suppression of bioactive LH (17) , which exerts its deleterious effect on the pregnancy outcome, or because of a long-term effect of high LH exerted on the oocytes prior to GnRH-a administration.
It seems, therefore, that the inappropriately raised LH concentrations rather than the presence of polycystic ovaries per se may be the critical factor in determining the risk for miscarriage (4, 16) . High prepregnancy LH levels may exert their deleterious effect on the pregnancy outcome directly by influencing the quality of the developing oocyte and consequently, of the resulting embryo (1, 4, 16) . This is further supported by the impaired quality of oocytes in PCOS patients (1) and the inverse correlation between oocyte maturity and LH:FSH ratio (4). However, it is possible that increased LH concentrations may have an additional effect on the endometrium, inducing abnormal synchronization among decidual maturation, embryonic development, and corpus luteum function (1,16). Nevertheless, Li et aL (22) failed to detect a correlation between high LH concentrations in the follicular phase and endometrial development, suggesting that the association between high LH levels and poor reproductive performance cannot be explained by abnormal implantation caused by retarded endometrial development.
CONCLUSIONS
It seems, therefore, that in PCOS patients stimulated for IVF with HMG, follicular-phase LH levels have an adverse effect on follicle and oocyte numbers as well as on oocyte quality. Moreover, an inappropriately raised LH appears to have a deleterious effect on the pregnancy outcome by being associated with a greater possibility for miscarriage. On the other hand, the administration of GnRH-a in the long desensitization protocol seems to reverse the detrimental effect of increased LH concentrations on follicular and oocyte development, whereas the beneficial effect on oocyte maturity, although significant, appears to be less profound. Furthermore, GnRH-a administration is associated with a decreased risk for early abortion. 
Clinical Utility of Adjuvant Growth Hormone in the Treatment of Patients with Polycystic Ovaries Undergoing In Vitro Fertilization
Polycystic ovarian disease .(PCOD) is a multifactorial endocrinopathy characterized by a wide range of variable manifestations such as oligoamenorrhea, clinical and biochemical signs of hyperandrogenism and hyperinsulinemia, a tendency to obesity, and typical ultrasound features. The identification of PCOD presents a number of difficulties and requires comprehensive clinical, ultrasonographic, morphological, and biochemical data. The clinical data include menstrual cycle disorders, ache, hirsutism, obesity, and metabolic manifestations of insuline resistance. Biochemical data include hyperandrogenism, an increased luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, and insulin resistance.
The treatment of PCOD with associated infertility remains a problem. The antiestrogen, clomiphene citrate (CC), is the drug of first choice. Ovulation can be induced in about 75-80% of women with PCOD treated with CC; however, the overall pregnancy rate is only 30-40%. The use of exogenous gonadotropins in PCOD patients is a more acceptable treatment for CC-resistant patients, with an overall pregnancy rate of 66%. However, this is associated with a high rate of multiple pregnancies and spontaneous abortions and a greater risk of ovarian hyperstimulation syndrome (OHSS). Purified urinary FSH, it is claimed, produces a lower incidence of OHSS. Cotreatment with gonadotropin releasing hormone analogue (GnRH-a) and human menopausal
